Novel Therapeutics for Metastatic Renal Cell Carcinoma

被引：18

作者：

Hutson, Thomas E. ^{[2
]}

Figlin, Robert A. ^{[1
]}

机构：

[1] City Hope Comprehens Canc Ctr, Div Med Oncol & Expt Therapeut, Duarte, CA 91010 USA

[2] Baylor Sammons Canc Ctr, Genitourinary Oncol Program, Dallas, TX USA

来源：

CANCER | 2009年 / 115卷 / 10期

关键词：

renal cell carcinoma; angiogenesis inhibitors; targeted therapy; sunitinib; sorafenib; temsirolimus; bevacizumab; everolimus; INTERFERON-ALPHA; DOUBLE-BLIND; PATIENTS PTS; CANCER; EXPRESSION; RCC; ANGIOPOIETIN-2; TIE2;

D O I：

10.1002/cncr.24235

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically during the past few years. Sunitinib malate, sorafenib tosylate, bevacizumab with interferon alpha, temsirolimus, and everolimus have improved clinical outcomes in randomized phase 3 trials by inhibiting the vascular endothelial growth factor and related pathways. Combinations and sequences of these agents are being evaluated. Other novel agents are in clinical development, some of which target novel pathways not yet exploited as therapy for RCC. Recently reported and ongoing clinical trials will help further define the role of these agents as therapy for metastatic RCC. Cancer 2009;115(10 suppl):2361-7. (C) 2009 American Cancer Society.

引用

页码：2361 / 2367

页数：7

共 29 条

[1]

*AMG 386 INV, AMG 386 INV BROCH

[2]

[Anonymous], J CLIN ONCOL S

[3]

[Anonymous], J CLIN ONCOL

[4] Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia [J].

Currie, MJ ;

Gunningham, SP ;

Turner, K ;

Han, C ;

Scott, PAE ;

Robinson, BA ;

Chong, W ;

Harris, AL ;

Fox, SB .

JOURNAL OF PATHOLOGY, 2002, 198 (04) :502-510

[5]

Eder JP, 2007, J CLIN ONCOL, V25

[6] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[7] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[8] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [J].

Figlin, R. A. ;

Hutson, T. E. ;

Tomczak, P. ;

Michaelson, M. D. ;

Bukowski, R. M. ;

Negrier, S. ;

Huang, X. ;

Kim, S. T. ;

Chen, I. ;

Motzer, R. J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[9] Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1 [J].

Gale, NW ;

Thurston, G ;

Hackett, SF ;

Renard, R ;

Wang, Q ;

McClain, J ;

Martin, C ;

Witte, C ;

Witte, MH ;

Jackson, D ;

Suri, C ;

Campochiaro, PA ;

Wiegand, SJ ;

Yancopoulos, GD .

DEVELOPMENTAL CELL, 2002, 3 (03) :411-423

[10] Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy [J].

Griffiths, RW ;

Gilham, DE ;

Dangoor, A ;

Ramani, V ;

Clarke, NW ;

Stern, PL ;

Hawkins, RE .

BRITISH JOURNAL OF CANCER, 2005, 93 (06) :670-677

← 1 2 3 →